<DOC>
	<DOCNO>NCT00594737</DOCNO>
	<brief_summary>Memantine approve use Alzheimer 's disease . Its mechanism action raise question whether also effective non-Alzheimer 's dementias frontotemporal dementia ( FTD ) , currently disease-modifying treatment . This open-label study probe effect memantine 15 outpatient diagnosed FTD , show objectively compare PET scan perform use medication . The specific type PET scan , FDG-PET , allow investigator gauge effect memantine cortical activity level . The investigator hypothesize subject memantine show normalization cortical metabolic activity .</brief_summary>
	<brief_title>Open Label Pilot Study Effects Memantine FDG-PET Frontotemporal Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Must meet criteria frontotemporal lobar degeneration ( FTD ) Neary et al . criterion . 28 Subjects may either behavioural aphasic variant FTD . Able undergo psychometric testing . Must reliable informant daily contact patient May take concurrent psychotropic medication , must stable dose regimen 3 month prior trial enrollment On basis physical examination , medical history ( include psychiatric neurological ) , result blood chemistry carry screening visit , patient investigator 's opinion consider healthy . Signed Informed Consent must obtain patient legally responsible representative informant prior initiate study specific procedure . Complaint recurrent persistent dizziness constipation Abnormal chemistry panel particular respect rule renal insufficiency failure . We exclude patient creatinine clearance ( CLcr ) &lt; 50ml/min , per Sakana equation men woman . Angina , myocardial infarction , severe hypertension , severe cardiac arrhythmia , unstable diabetes mellitus , new abnormality EKG within past year . Any current malignancy , clinically significant hematological , endocrine , renal , hepatic , gastrointestinal nondementia neurological disease . If condition stable least past year judge investigator interfere patient 's participation study , patient may include . Basal cell carcinoma exception . NonEnglish speaking , cognitive test English . Evidence neurological psychiatric disorder preclude diagnosis FTD ( include , limited , stroke , Parkinson 's disease , psychotic disorder , severe bipolar unipolar depression ) within past year Current prior history uncontrolled seizure disorder , due seizure report adverse event memantine . Patients suspect alcohol substance abuse within last 1 year . If past history abuse dependence must abstinent 1 year continue progression dementia despite abstinence . Patients active delusion hallucination time screen . Female patient least two year postmenopausal surgically sterile . Premenopausal woman exclude ; almost woman postmenopausal age onset FTD , anticipate exclude one potential subject basis one exclusion criterion . Use investigational drug participation another investigational drug study within 3 month screen . Patients previously treat memantine participate investigational study memantine . Patients history severe drug allergy hypersensitivity know hypersensitivity amantadine memantine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PET</keyword>
	<keyword>frontotemporal dementia</keyword>
	<keyword>memantine</keyword>
	<keyword>Pick 's disease</keyword>
</DOC>